Drug intelligence / Profile preview

LR20061

Development stage: Preclinical
Lead developer: LG Chem

Overview

LR20061 is a research-stage therapeutic candidate being developed by LG Chem for the treatment of atopic dermatitis. Currently in the discovery or preclinical phase, the program's specific molecular target and modality have not been publicly disclosed by the sponsor. It is part of LG Chem's immunology pipeline, which focuses on developing novel treatments for chronic inflammatory skin conditions. As a research-stage asset, it represents an early-stage exploration into the pathophysiology of atopic dermatitis, aiming to address unmet needs in the management of this prevalent dermatological disease.

Beyond the preview

Go deeper on LR20061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR20061.

Explore the full profile